• Explore /
  • Poster
  • / An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).

An investigator initiated multicenter phase I/II study of TAS-102 with bevacizumab for metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE).

Abstract Poster

Authors

null

Yasutoshi Kuboki

Department of GI oncology, National Cancer Center Hospital East, Japan, Kashiwa, Japan

Yasutoshi Kuboki , Tomohiro Nishina , Eiji Shinozaki , Kentaro Yamazaki , Kohei Shitara , Wataru Okamoto , Takeshi Kajiwara , Toshihiko Matsumoto , Takahiro Tsushima , Nobuo Mochizuki , Miki Fukutani , Masako Nakamoto , Hiromi Hasegawa , Ayako Sugama , Shogo Nomura , Akihiro Sato , Atsushi Ohtsu , Takayuki Yoshino

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer

Clinical Trial Registration Number

000012883

Citation

J Clin Oncol 33, 2015 (suppl; abstr 3544)

DOI

10.1200/jco.2015.33.15_suppl.3544

Abstract #

3544

Poster Bd #

36

Abstract Disclosures

Similar Posters

First Author: Nieves Martinez Lago

First Author: Hirokazu Shoji

Poster

2024 ASCO Gastrointestinal Cancers Symposium

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

First Author: Patrick M Boland

First Author: Atsushi Ishiguro